Urethral Stents Sales

Urethral Stents Sales Market Outlook

The global urethral stents market is projected to reach approximately USD 4.5 billion by 2035, growing at a robust CAGR of 7.5% during the forecast period from 2025 to 2035. This growth is primarily driven by the increasing prevalence of urological disorders, such as benign prostatic hyperplasia and urethral strictures, which necessitate the use of stenting procedures as an effective therapeutic option. Moreover, advancements in the design and technology of urethral stents, including the development of drug-eluting and biodegradable stents, are further propelling market growth. The rising geriatric population, who are more susceptible to urological conditions, along with the growing demand for minimally invasive surgeries, is also significantly contributing to the expansion of the urethral stents market. With improvements in healthcare infrastructure and increased healthcare spending in emerging economies, the market is well-positioned for future growth.

Growth Factor of the Market

The growth of the urethral stents market is significantly influenced by several key factors that elevate its demand across various healthcare settings. One of the primary drivers is the global increase in the incidence of urological conditions, particularly amongst the aging population, which leads to a greater requirement for effective management solutions. Additionally, technological advancements in stent materials and designs, such as the introduction of drug-eluting stents that reduce the risk of complications, are enhancing patient outcomes and encouraging more healthcare providers to adopt these devices. The trend towards outpatient procedures and minimally invasive surgeries is also a pivotal factor, as urethral stenting is often less invasive than alternative surgical options. Furthermore, rising awareness regarding the importance of early diagnosis and treatment of urological disorders is driving patients to seek medical assistance, thereby bolstering the market. Lastly, favorable reimbursement policies in developed regions are promoting the use of urethral stents, making them more accessible to a larger patient population.

Key Highlights of the Market

• The global urethral stents market is anticipated to witness a CAGR of 7.5% from 2025 to 2035.
• Technological advancements, including the development of drug-eluting stents, are transforming treatment modalities.
• The increasing incidence of urological disorders is a significant driver of market growth.
• Minimally invasive surgery trends are promoting wider adoption of urethral stents in clinical settings.
• Emerging economies are experiencing a rise in healthcare investments, providing new market opportunities.

By Product Type

Metal Stents:

Metal stents are widely utilized in the management of various urological conditions due to their strength and durability. These stents, often made from stainless steel or nickel-titanium alloys, are designed to maintain patency in the urethra and bladder, preventing blockages caused by conditions such as urethral strictures. Their ability to provide a rigid support structure makes them ideal for patients with complex urological issues. Furthermore, metal stents can be coated with biocompatible materials to enhance their functionality and reduce the risk of encrustation and infection. As a result, metal stents hold a significant market share and are favored by urologists for their reliability and long-term efficacy in patient care.

Silicone Stents:

Silicone stents are favored in the urethral stenting market for their flexibility and biocompatibility. These stents are particularly advantageous for patients who require temporary stenting, such as those recovering from surgical procedures or who have intermittent urethral obstructions. Silicone stents are less likely to cause irritation to the urethral lining, which makes them a comfortable option for patients. They are often used in combination with other devices to manage complications more effectively. The ease of removal and replacement associated with silicone stents also adds to their appeal, contributing to their growing adoption in clinical practice.

Biodegradable Stents:

Biodegradable stents are an innovative solution gaining traction in the urethral stents market due to their ability to dissolve over time, thus eliminating the need for surgical removal. Made from materials that gradually break down in the body, these stents provide temporary support while reducing the risk of long-term complications associated with traditional stents. The primary advantage of biodegradable stents is their ability to minimize the risk of encrustation and infection while providing effective urethral drainage. As healthcare providers seek more patient-friendly solutions, biodegradable stents are expected to gain popularity, particularly among patients concerned about the long-term presence of foreign materials in their bodies.

Drug-Eluting Stents:

Drug-eluting stents represent a significant advancement in urethral stenting technology, designed to release therapeutic agents over time to prevent the recurrence of urethral strictures and enhance healing. These stents are coated with a drug that inhibits tissue growth, thereby minimizing the risk of obstruction after the stent is placed. The effectiveness of drug-eluting stents in preventing complications such as re-stricture is a driving factor in their increasing market share. Patients appreciate the reduced need for additional procedures and interventions, making drug-eluting stents a preferred choice among healthcare professionals aiming for optimal patient outcomes.

Hybrid Stents:

Hybrid stents combine features of both metal and biodegradable stents, offering a unique solution for patients requiring stenting for prolonged periods. These stents are engineered to provide structural support while also allowing for gradual biodegradation, striking a balance between durability and safety. Hybrid stents can be particularly useful in complex cases where traditional stenting methods may not suffice. The flexibility and adaptability of hybrid stents are becoming increasingly attractive to surgeons and patients alike, thereby contributing to their gradual adoption in urological practices.

By Application

Benign Prostatic Hyperplasia:

Benign prostatic hyperplasia (BPH) is a common condition among older men, characterized by the enlargement of the prostate gland that can impede urinary flow. Urethral stents are employed as a treatment option to alleviate urinary obstruction caused by BPH. The use of stenting in BPH patients provides immediate relief from symptoms, improving quality of life for those affected. As the incidence of BPH rises with age, the demand for effective management strategies, including the use of urethral stents, continues to grow, positioning this application as a significant segment of the urethral stents market.

Urethral Stricture:

Urethral stricture refers to the narrowing of the urethra, often resulting from trauma, infection, or prior surgeries. Stenting is a vital approach to manage this condition, as stents help maintain urethral patency and facilitate urine flow. The success of stenting in treating urethral strictures has led to increased adoption among healthcare providers, driving the segment's growth. Ongoing advances in stent technology also promise enhanced patient outcomes, making urethral strictures an essential focus area within the urethral stents market.

Urinary Incontinence:

Urinary incontinence, which affects a significant portion of the population, involves the involuntary leakage of urine. Urethral stents can play a role in the management of urinary incontinence, particularly in cases where anatomical abnormalities or obstructions are present. The use of stents for this application provides a minimally invasive option that can offer substantial relief from symptoms. The increasing recognition of urinary incontinence as a prevalent issue and the growing preference for minimally invasive treatments are driving growth within this segment of the urethral stents market.

Ureteral Obstruction:

Ureteral obstruction is a serious condition that can lead to kidney damage if not addressed promptly. Urethral stents are often used to restore proper urine flow in patients experiencing ureteral obstruction due to various causes, such as kidney stones or tumors. The effectiveness of stenting in alleviating such obstructions is widely recognized, leading to increased patient acceptance of this treatment option. As awareness of the severity of ureteral obstruction rises and healthcare providers seek effective interventions, this application is anticipated to experience robust growth in the urethral stents market.

Others:

The “Others” category encompasses a range of applications for urethral stents beyond the primary indications mentioned. This segment includes conditions such as urethral trauma, post-surgical complications, and other urological disorders that may require stenting for effective management. The versatility of urethral stents allows them to be employed in various clinical situations, addressing the unique needs of different patient populations. As research continues to explore new applications for stenting technology, this segment is likely to see increased growth opportunities and expanded use in clinical practice.

By Distribution Channel

Hospitals:

Hospitals remain the primary distribution channel for urethral stents, owing to their centralized healthcare services and the availability of specialized urology departments. In hospital settings, patients receive comprehensive care, including diagnosis, treatment, and post-operative monitoring, making it an ideal environment for stent placement procedures. Furthermore, hospitals often have the necessary facilities and personnel to handle complex cases, which contributes to their dominance in the market. Given the increasing prevalence of urological conditions, the hospital segment is expected to experience sustained growth as more patients seek treatment in these settings.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) are emerging as a significant distribution channel for urethral stents due to their focus on outpatient procedures. These centers provide a cost-effective alternative for patients requiring stenting, as they often charge lower fees compared to hospitals. The growing trend towards minimally invasive and outpatient surgeries has led to a rise in the number of ASCs, further driving the demand for urethral stents. ASCs offer convenience and efficiency for patients, making them an attractive option for both patients and healthcare providers, leading to their increasing market share in the urethral stents sector.

Specialty Clinics:

Specialty clinics, particularly those focused on urology, play an important role in the distribution of urethral stents. These clinics are staffed by urology experts who are well-versed in the latest techniques and technologies for stenting procedures. Patients are increasingly seeking care from specialty clinics that offer targeted treatments for specific urological conditions, enhancing patient outcomes and satisfaction. The growth of specialty clinics is anticipated to boost the urethral stents market, as they provide tailored care that addresses the unique needs of patients facing urological challenges.

Online Sales:

The rise of e-commerce has transformed the distribution landscape for medical devices, including urethral stents. Online sales channels provide greater accessibility for healthcare providers and patients seeking stenting solutions. The convenience of purchasing medical devices online, combined with the ability to access a broader range of products, is encouraging more healthcare facilities to consider online distributors for their stent procurement. As digitalization continues to shape the healthcare industry, online sales channels are expected to increase their presence in the urethral stents market.

Others:

The “Others” category encompasses various distribution channels beyond the primary ones mentioned, including wholesale distributors, pharmacies, and direct sales from manufacturers. These channels may cater to specific market segments or geographic regions, providing additional access to urethral stents for healthcare providers. The diversification of distribution strategies allows for a more comprehensive approach to market access, ensuring that patients have timely access to necessary stenting products. The emergence of new distribution methods is anticipated to contribute to the overall growth of the urethral stents market.

By Material Type

Metal:

Metal stents are a cornerstone in the urethral stents market, renowned for their strength and durability. Typically constructed from materials like stainless steel and nickel-titanium alloys, these stents provide the necessary support to maintain urethral patency. Their rigidity allows them to withstand pressure and prevent collapse, which is particularly crucial in managing conditions such as urethral strictures. Additionally, advancements in coating technologies have improved the biocompatibility of metal stents, reducing the risk of complications such as encrustation and infection. As a result, metal stents continue to hold a significant market share, with ongoing innovations enhancing their performance and safety for patients.

Silicone:

Silicone stents have gained popularity in the urethral stents market due to their inherent flexibility and biocompatibility. Designed to be less irritating to the urethra, silicone stents are especially suitable for temporary applications, such as following surgery or for patients with intermittent obstructions. Their soft nature allows for comfortable placement and removal, contributing to a positive patient experience. The versatility of silicone stents enables them to be used in various clinical scenarios, making them a vital segment of the urethral stents market and appealing to healthcare providers who prioritize patient comfort.

Polymer:

Polymer-based stents are an innovative addition to the urethral stents market, offering a range of benefits over traditional materials. These stents are designed to be lightweight and tailored to fit individual anatomical needs, enhancing patient comfort and outcomes. Polymer materials can also be engineered to incorporate drug-eluting properties, which help prevent complications such as re-stricture. As the demand for advanced stenting solutions increases, polymer stents are expected to gain traction, particularly among patients seeking minimally invasive treatment options with reduced side effects.

Bioabsorbable Materials:

Bioabsorbable materials are revolutionizing the urethral stents market by providing a temporary solution that eliminates the need for surgical removal. Stents made from bioabsorbable materials gradually dissolve within the body over time, reducing the risk of long-term complications associated with traditional stents. The appeal of bioabsorbable stents lies in their ability to maintain urethral patency during the critical healing period without leaving a permanent foreign object in the body. As healthcare providers increasingly adopt strategies that prioritize patient safety and comfort, the use of stents made from bioabsorbable materials is expected to rise significantly.

Others:

The "Others" category encompasses a variety of materials utilized in urethral stent manufacturing, including combinations of the aforementioned materials and emerging alternatives. These materials may offer unique properties that cater to specific clinical needs, such as enhanced biocompatibility or improved mechanical strength. As research and development in stent technologies continue to evolve, the exploration of new materials will drive innovation within the market, providing healthcare providers with additional options to meet diverse patient requirements.

By Region

The urethral stents market demonstrates significant variation across different regions, largely influenced by healthcare infrastructure, prevalence of urological conditions, and market dynamics. North America is currently the largest market, driven by advanced healthcare systems, high patient awareness, and the presence of key manufacturers. The North American market is projected to grow at a CAGR of 6.8% from 2025 to 2035, as the increasing incidence of urological diseases and a preference for minimally invasive procedures continue to drive demand. Furthermore, favorable reimbursement policies and innovations in stent technology are expected to boost market growth in this region.

Europe follows closely behind North America in the urethral stents market, characterized by its well-established healthcare system and increasing investments in healthcare infrastructure. The European market is witnessing a growing trend towards outpatient surgeries, contributing to an increase in the adoption of urethral stents in clinical practice. Furthermore, rising awareness regarding urological disorders and the availability of advanced treatment options are expected to fuel market growth in Europe. Meanwhile, the Asia Pacific region is emerging as a potential growth market, driven by improving healthcare access, rising disposable incomes, and increasing prevalence of urological conditions. With a CAGR of 8.2%, the Asia Pacific region is anticipated to see substantial growth opportunities in the urethral stents market as more patients seek effective treatment solutions.

Opportunities

The urethral stents market is poised for numerous opportunities as advancements in technology and increasing healthcare investments create a favorable environment for growth. The rising incidence of urological disorders, particularly among the aging population, presents a significant opportunity for market players to develop innovative stenting solutions that cater to the needs of this demographic. Moreover, the growing trend towards minimally invasive procedures is prompting healthcare providers to seek new technologies that enhance patient outcomes while reducing recovery times. Companies that invest in research and development to create advanced stents, such as drug-eluting and biodegradable options, are likely to capture a significant market share as they address the evolving needs of patients and healthcare providers alike.

In addition to technological advancements, expanding healthcare infrastructure in emerging economies offers exciting opportunities for the urethral stents market. Increased healthcare spending in regions like Asia Pacific and Latin America is facilitating greater access to advanced medical devices, including urethral stents. As healthcare providers in these regions adopt modern treatment methodologies, the demand for effective stenting solutions is expected to grow. Furthermore, strategic collaborations between manufacturers and healthcare institutions will enhance product availability and accessibility, ultimately benefiting patients and driving market expansion. Companies that successfully navigate these opportunities will be well-positioned to achieve sustained growth in the global urethral stents market.

Threats

Despite the positive outlook for the urethral stents market, several threats could impede growth and market stability. One of the primary threats is the increasing regulatory scrutiny surrounding medical devices, which can lead to delays in product approvals and increased costs for manufacturers. Stricter regulations may require extensive clinical trials and additional documentation, potentially hindering the introduction of innovative stenting technologies. Moreover, the potential for product recalls due to safety concerns can adversely affect brand reputation and consumer trust, creating challenges for companies operating in the urethral stents market. Additionally, the presence of alternative treatment options, such as surgical interventions and pharmacological therapies, poses a competitive threat, as patients may opt for these alternatives if they perceive them to be more effective or safer.

Another significant threat to the urethral stents market is the rising prevalence of hospital-acquired infections, which can lead to increased scrutiny of medical devices used during procedures. The potential for infections associated with stent placement can deter healthcare providers from opting for stenting solutions, impacting market demand. Furthermore, fluctuations in raw material prices can affect manufacturing costs and pricing strategies, potentially limiting the ability of companies to compete effectively. Addressing these threats will require proactive risk management strategies and a commitment to maintaining high-quality standards in product development and manufacturing.

Competitor Outlook

• Boston Scientific Corporation
• Cook Medical Inc.
• Coloplast A/S
• Teleflex Incorporated
• Medtronic plc
• Richard Wolf GmbH
• UroLift
• Bard Medical Division
• Endo Pharmaceuticals Inc.
• Hollister Incorporated
• ConMed Corporation
• Merit Medical Systems Inc.
• Smith & Nephew plc
• Alvimedica
• Surmodics, Inc.

The competitive landscape of the urethral stents market is characterized by a diverse range of players, including established multinational corporations and emerging companies. Major players in the market are investing heavily in research and development to introduce innovative stenting solutions that address the evolving needs of healthcare providers and patients. The strategic focus on product differentiation, particularly through advancements in stent materials and designs, is becoming increasingly important as companies seek to capture a larger market share. Additionally, partnerships and collaborations between manufacturers and healthcare institutions are fostering the development of tailored solutions that enhance patient outcomes while increasing market penetration.

Boston Scientific Corporation is a key player in the urethral stents market, known for its extensive portfolio of urological products, including innovative stenting technologies. The company has made significant investments in research and development, leading to the introduction of advanced stents that incorporate drug-eluting properties. Similarly, Cook Medical Inc. has established a strong presence in the market with its wide range of urethral stents designed for various clinical applications. The company's focus on patient-centered solutions and commitment to quality have positioned it as a trusted provider in the field of urology.

Coloplast A/S is another prominent competitor in the urethral stents market, with a robust product offering that includes silicone and bioabsorbable stents. The company's emphasis on improving patient comfort and quality of life has driven its success in the market. Teleflex Incorporated is also a notable player, recognized for its innovative stenting solutions and focus on enhancing clinical outcomes. The competitive landscape is further intensified by the entry of emerging firms, which are leveraging advancements in technology to develop new and improved stenting options that meet the diverse needs of patients and healthcare providers alike.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 UroLift
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Alvimedica
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Coloplast A/S
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Medtronic plc
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Surmodics, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Cook Medical Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Richard Wolf GmbH
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 ConMed Corporation
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Smith & Nephew plc
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Bard Medical Division
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Teleflex Incorporated
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Hollister Incorporated
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Endo Pharmaceuticals Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Merit Medical Systems Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Boston Scientific Corporation
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Urethral Stents Sales Market, By Application
    • 6.1.1 Benign Prostatic Hyperplasia
    • 6.1.2 Urethral Stricture
    • 6.1.3 Urinary Incontinence
    • 6.1.4 Ureteral Obstruction
    • 6.1.5 Others
  • 6.2 Urethral Stents Sales Market, By Product Type
    • 6.2.1 Metal Stents
    • 6.2.2 Silicone Stents
    • 6.2.3 Biodegradable Stents
    • 6.2.4 Drug-Eluting Stents
    • 6.2.5 Hybrid Stents
  • 6.3 Urethral Stents Sales Market, By Material Type
    • 6.3.1 Metal
    • 6.3.2 Silicone
    • 6.3.3 Polymer
    • 6.3.4 Bioabsorbable Materials
    • 6.3.5 Others
  • 6.4 Urethral Stents Sales Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Ambulatory Surgical Centers
    • 6.4.3 Specialty Clinics
    • 6.4.4 Online Sales
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Urethral Stents Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Urethral Stents Sales market is categorized based on

By Product Type

• Metal Stents
• Silicone Stents
• Biodegradable Stents
• Drug-Eluting Stents
• Hybrid Stents

By Application

• Benign Prostatic Hyperplasia
• Urethral Stricture
• Urinary Incontinence
• Ureteral Obstruction
• Others

By Distribution Channel

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Online Sales
• Others

By Material Type

• Metal
• Silicone
• Polymer
• Bioabsorbable Materials
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Boston Scientific Corporation
• Cook Medical Inc.
• Coloplast A/S
• Teleflex Incorporated
• Medtronic plc
• Richard Wolf GmbH
• UroLift
• Bard Medical Division
• Endo Pharmaceuticals Inc.
• Hollister Incorporated
• ConMed Corporation
• Merit Medical Systems Inc.
• Smith & Nephew plc
• Alvimedica
• Surmodics, Inc.